Randomized clinical trial on the use of antispasmodic drugs in barium enema: impact on radiological practice.
OBJECTIVE
To assess the willingness of radiologists to change their practice when the results of a randomized clinical trial (RCT) on the use of antispasmodic drugs in barium enema are presented.


METHODS
During the years 1994 and 1995 two postal questionnaires were sent to 481 practicing radiologists who were all members of the Netherlands Society of Radiology. In the first questionnaire the respondents were asked to give the characteristics of their practices in performing daily barium enema. The data from this questionnaire was used as a reference. The second questionnaire was sent to the respondents together with an abstract on the randomized clinical trial supporting the use of antispasmodic drugs in barium enema. We also indicated a preference for Buscopan over Glucagon as the antispasmodic drug. The willingness to change prescription habits was measured by comparing the data of the two questionnaires.


RESULTS
Of 481 practicing radiologists, 312 responded to the first questionnaire and gave information of their prescription habits (response rate 64%). These 312 responders were sent an abstract of the RCT and were asked to fill out a second questionnaire to determine their willingness to change their practice. Two hundred and sixty-seven radiologists responded (response rate 86%). A significant number of 119 (51%) were willing to increase the use of antispasmodic drugs. A significant number of 128 (55%) chose to increase the use of Buscopan, while a significant number of 81 (32%) were willing to decrease the use of Glucagon.


CONCLUSIONS
Direct exposure to the results of an RCT recommending the use of antispasmodic drugs in barium enema, especially Buscopan, is likely to increase its use by practicing radiologists.
Goei
R
R
Department of Radiology, Atrium Medical Centre, P.O. Box 4446, 6401 CX, Heerlen, The Netherlands.
Kessels
A H
AH
Nix
M
M
Knipschild
P G
PG
D001291:Attitude of Health Personnel; D001466:Barium Sulfate / Q000008:administration & dosage; D002086:Butylscopolammonium Bromide / Q000627:therapeutic use; D016009:Chi-Square Distribution; D003287:Contrast Media / Q000008:administration & dosage*; D004733:Enema; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D005934:Glucagon / Q000627:therapeutic use; D006801:Humans; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D009426:Netherlands; D010276:Parasympatholytics / Q000627:therapeutic use*; D010818:Practice Patterns, Physicians'; D011446:Prospective Studies; D011871:Radiology; D011795:Surveys and Questionnaires
D003287:Contrast Media; D005765:Gastrointestinal Agents; D018727:Muscarinic Antagonists; D010276:Parasympatholytics; D001466:Barium Sulfate; D002086:Butylscopolammonium Bromide; D005934:Glucagon